UBS Group Reiterates CHF 237 Price Target for Roche (ROG)

Roche (VTX:ROG) has been assigned a CHF 237 price objective by analysts at UBS Group in a research report issued to clients and investors on Tuesday, www.boersen-zeitung.de reports. The firm presently has a “neutral” rating on the healthcare company’s stock. UBS Group’s target price suggests a potential upside of 6.80% from the stock’s current price.

Several other analysts also recently weighed in on ROG. Morgan Stanley set a CHF 260 price objective on Roche and gave the stock a “neutral” rating in a research report on Friday, November 17th. Deutsche Bank set a CHF 264 price objective on Roche and gave the stock a “neutral” rating in a research report on Tuesday, December 12th. Liberum Capital set a CHF 279 price objective on Roche and gave the stock a “buy” rating in a research report on Wednesday, November 22nd. Goldman Sachs Group set a CHF 325 price objective on Roche and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Finally, Barclays set a CHF 295 price objective on Roche and gave the stock a “buy” rating in a research report on Monday, February 5th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of CHF 256.05.

Shares of Roche (VTX:ROG) opened at CHF 221.90 on Tuesday. The stock has a market capitalization of $192,070.00 and a price-to-earnings ratio of 22.10. Roche has a 1-year low of CHF 214.30 and a 1-year high of CHF 273.

TRADEMARK VIOLATION WARNING: “UBS Group Reiterates CHF 237 Price Target for Roche (ROG)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/20/ubs-group-reiterates-chf-237-price-target-for-roche-rog.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply